Faeth reports 33% confirmed response rate for PIKTOR-paclitaxel in Phase 2 endometrial cancer trial
Bitget2026/11/09 12:03- Faeth Therapeutics reported positive preliminary Phase 2 results for PIKTOR with paclitaxel in previously treated advanced endometrial cancer.
- The ongoing trial showed tumor responses and disease control, with some responses deepening during treatment.
- Treatment-related side effects led to few discontinuations; no treatment-related deaths occurred.
- Results support plans to advance into a Phase 3 registrational trial, subject to regulatory alignment.
- Management will discuss the findings during a webcast today at 8 a.m. ET.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
